Alcidion Group (ALC) investor relations material

Executive summary

• Achieved record half-year revenue of $25.5M (AUD 25.5M), up 44% year-over-year, driven by recurring revenue and major contract expansions in both Australia/New Zealand and the UK.

• Underlying EBITDA reached $4.2M, a 675% increase year-over-year, with net profit after tax of $1.33M, reversing a prior loss.

• Annual Recurring Revenue (ARR) reached $31.1M as of December 2025, up 29% year-over-year.

• Flagship Miya Precision platform expanded to over 400 hospitals, delivering real-time clinical decision support.

• Net cash position of $14.2M and no debt as of 31 December 2025.

Financial highlights

• H1 revenue of $25.5M, with $7.8M increase over prior year; UK contributed $5.8M of the increase.

• Recurring revenue made up 76% of H1 revenue, with significant growth in both ANZ and UK regions.

• Gross margin at 83%, down from 87% year-over-year, due to higher third-party product content.

• Operating cash outflow improved to $2.6M, a $1.7M improvement year-over-year.

• Ended H1 with $14.2M in cash, up from $7.7M last year.

Outlook and guidance

• FY26 revenue expected to exceed $50M, with EBITDA above $5M and positive operating cash flow.

• Contracted and renewal revenue for FY26 at $43.1M as of 31 Dec 2025, excluding potential UHSussex contract.

• Anticipated UHSussex contract could exceed $35M over seven years, with deployment targeted for Q4 FY26.

• Guidance includes anticipated upfront fee from UHS Sussex contract and marginal increases in OpEx.

• Gross margin expected to return to mid-to-high 80s in future years.